Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?

In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...